Inspiratory flows and volumes in subjects with cystic fibrosis using a new dry powder inhaler device

Open Respiratory Medicine Journal

Volumn 8, Issue 1, 2014, Pages 1-7

  Elkins, Mark R ^a   Robinson, Philip ^b   Anderson, Sandra D ^a   Perry, Clare P ^a   Daviskas, Evangelia ^a   Charlton, Brett ^c  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c Pharmaxis Ltd   (Australia)

Author keywords

Clinical trials; Cystic fibrosis; Dry powder inhaler; High resistance inhaler; Peak inspiratory flow; Respiratory function tests

Indexed keywords

MANNITOL;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CYSTIC FIBROSIS; DRY POWDER INHALER; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INSPIRATORY RESERVE VOLUME; LUNG FUNCTION; MALE; MULTICENTER STUDY; OPEN STUDY; PEAK INSPIRATORY FLOW; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; SAFETY; SPIROMETER; DEVICE SAFETY; INSPIRATORY VOLUME; OBSERVATIONAL STUDY; RESPIRATORY TRACT PARAMETERS; SPIROMETRY;

EID: 84896892682     PISSN: None     EISSN: 18743064     Source Type: Journal    
DOI: 10.2174/1874306401408010001     Document Type: Article

References (17)

1. Glover W, Chan H-K, Eberl S, Daviskas E, Verschuer J. Effect of particle size of dry powder mannitol on the lung deposition in healthy volunteers. Int J Pharm 2008; 349: 314-22.
2. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general US population. Am J Respir Crit Care Med 1999; 159: 179-87.
3. Wang X, Dockery DW, Wypij D, Fay ME, Ferris BG Jr. Pulmonary function of children aged 6-18 years of age. Pediatric Pulm 1993; 15: 75-88.
4. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005; 26: 319-38.
5. Tiddens HA, Geller DE, Challoner P, et al. Effect of dry powder inhaler resistance on the inspiratory flow rates and volumes of cystic fibrosis subjects of six years and older. J Aerosol Med 2006; 19: 456-65.
6. Clark AR, Hollingworth AM. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers-Implications for in vitro testing. J Aerosol Med 1993; 6: 99-110.
7. Terzano C, Colombo P. State of the art and new perspectives on dry powder inhalers. Eur Rev Med Pharm Sci 1999; 3: 247-54.
8. Chew NYK, Chan H-K. Influence of particle size, airflow, and inhaler device on the dispersion of mannitol as aerosols. Pharmacol Res 1999; 16: 1098-103.
9. Chew NYK, Chan H-K. In vitro aerosol performance and dose uniformity between the Foradile Aerolizer and the Oxis Turbuhaler. J Aerosol Med 2001; 14: 495-501.
10. Broeders MEAC, Molema J, Vermue NA, Folgering HT. Peak inspiratory flow rate and slope of the inhalation profiles in dry powder inhalers. Eur Respir J 2001; 18: 780-3.
11. European Pharmacopoeia (Ph. Eur.).
12. United States Pharmacopeia (USP).
13. Bronchitol European Patient Information Leaflet. Version 19 June 2012 (Pharmaxis Pharmaceuticals Ltd) on the EMA website: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_P roduct_Information/human/001252/WC500130592.pdf
14. Glover W, Chan H-K, Eberl S, Daviskas E, Anderson S. Lung deposition of mannitol powder aerosol in healthy subjects. J Aerosol Med 2006; 19: 522-32.
15. Laube BL, Janssens HM, de Jongh FHC, et al. ERS/ISAM Task Force Report. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J 2011; 37: 1308-31.
16. Bilton D, Robinson P, Cooper P, et al. Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study. Eur Respir J 2011; 38: 1071-80.
17. Aitken ML, Bellon G, De Boeck K, et al. Long-term inhaled dry powder mannitol in cystic fibrosis. An International randomized study. Am J Respir Crit Care Med 2012; 185: 645-52.